Loading...

Liminal BioSciences Inc.

LMNL•NASDAQ
Healthcare
Biotechnology
$8.50
$0.010(0.12%)

Liminal BioSciences Inc. (LMNL) Stock Overview

Explore Liminal BioSciences Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.0/100

Key Financials

Market Cap27.6M
P/E Ratio-1.24
EPS (TTM)$-6.83
ROE-0.73%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$1.51

LMNL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Liminal BioSciences Inc. (LMNL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.51.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.24 and a market capitalization of 27.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for LMNLStats details for LMNL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for LMNLAnalyst Recommendations details for LMNL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

CEO

Bruce Pritchard BA, CA, FIOD

Employees

251

Headquarters

440 Armand-Frappier Boulevard, Laval, QC

Founded

2009

Frequently Asked Questions

;